Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer

ONCOLOGY

Volumn 18, Issue 6, 2004, Pages 762-768

  Whisenant, Jonathan ^a   Venook, Alan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLOXURIDINE; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; HEPATIC ARTERY; HUMAN; INFUSION PUMP; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLOXURIDINE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS;

EID: 33645786599     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Kato T, Yasui K, Hirai T, et al: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: Analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46:S22-S31, 2003.
2. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 30:969-985, 1954.
3. Buchwald H, Grage TB, Vassilopoulos PP, et al: Intraarterial infusion chemotherapy for 0hepatic carcinoma using a totally implantable infusion pump. Cancer 45:866-869, 1980.
4. Habbe T, McCowan T, Goertzen T, et al: Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. J Vasc Interv Radiol 9(2):233-239, 1998.
5. Ensminger WD, Rosowsky A, Raso V, et al: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1978.
6. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107(4):459-465, 1987.
7. Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern Oncology Group Trial. J Clin Oncol 7:1646-1654, 1989.
8. Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685-693, 1987.
9. Martin JK Jr, O'Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 125:1022-1027, 1990.
10. Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 10(7):1112-1118, 1992.
11. Allen-Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:1255-1260, 1994.
12. Harmantas A, Rotstein LE, Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Cancer 78:1639-1645, 1996.
13. Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88(5):252-258, 1996
14. Campbell CA, Burns RC, Sitzmann JV, et al: Regional chemotherapy devices: Effect of experience and anatomy on complications. J Clin Oncol 11:822-826, 1993.
15. Hohn DC, Rayner AA, Exonomou JS, et al: Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer 57:465-470, 1986.
16. Curley SA, Chase JL, Roh MS, et al: Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 114:928-935, 1993.
17. Stagg RJ, Venook AP, Chase JL, et al: Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 83:423-428, 1991.
18. Kemeny N, Seiter K, Niedzwiecki D, et al: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 69:327-334, 1992.
19. Kemeny N, Seiter K, Conti JA, et al: Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. Cancer 73:1134-1142, 1994.
20. Kemeny N, Conti JA, Cohen A, et al: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12:2288-2295, 1994.
21. Lorenz M, Mueller H: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuritine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18:243-254, 2000.
22. Kerr DJ, McArdle CS, Ledermann J, et al: Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: A multicentre randomized trial. Lancet 361:368-373, 2003
23. Heinrich S, Petrowsky H, Schwinnen I, et al: Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. Surgery 133:40-48, 2003.
24. Fordy C, Burke D, Earlam S, et al: Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Br J Cancer 72:1023-1025, 1995.
25. Kemeny N, Niedzwiecki D, Hollis DR, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A CALGB randomized trial of efficacy, quality of life, cost effectiveness, and molecular markers. Proc Am Soc Clin Oncol 22:252, 2003.
26. Kemeny N, Conti JA, Sigurdson E, et al: A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer 71:1964-1971, 1993.
27. Safi F, Bittner R, Roscher R, et al: Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Cancer 64:379-387, 1989.
28. Kemeny N, Gonen M, Sullivan D, et al: Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19:2687-2695, 2001.
29. Paty P, Fong Y, Harris R, et al: Update of phase I studies of hepatic arterial infusion of floxuridine and dexamethasone pous: Systemic oxaliplatin and irinotecan or systemic oxaliplatin snd fluorouracil and leucovorin for unresectable hepatic metastases from colorectal cancer (abstract 1160). Proc Am Soc Clin Oncol 22:289, 2003.
30. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer. A randomized GERCOR study. J Clin Oncol 22:229-237, 2004.
31. Fiorentini G, Rossi S, Dentico P, et al: Irinotecan hepatic atorial infusion chemotherapy for hepatic metastases from colorectal cancer: A phase II clinical study. Tumori 89:382-384, 2003.
32. Boige V, Lacombe S, De Baere T, et al: Hepatic arterial infusion oxaliplatin combined with intravenous 5-FU and folinic acid in non respectable liver metastasis of colorectal cancer: A promising option for failures to systemic chemotherapy (abstract 1170). Proc Am Soc Clin Oncol 22:291, 2003.
33. Meric F, Patt Y, Curley SA, et al: Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 7:490-495, 2000.
34. Personal communication.
35. Kemeny MM, Goldberg D, Beatty JD, et al: Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 57:492-498, 1986.
36. Wagman LD, Kemeny MM, Leong L, et al: Prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8:1885-1893, 1990.
37. Ambiru S, Miyazaki M, Ito H, et al: Adjuvant regional chemotherapy after hepatic resection for colorectal metastases. Br J Surg 86:1025-1031, 1999.
38. Lorenz M, Mueller H, Schramm H, et al: Randomized, multicenter trial of surgery versus surgery followed by adjuvant arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. J Clin Oncol 228:756-762, 2000.
39. Kemeny N, Huang Y, Cohen A, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039-2048, 1999.
40. Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - An Intergroup study. J Clin Oncol 20:1499-1505, 2002.
41. DeGramont A, Banzi M, Navarro M, et al: Oxaliplatin/5FU/leucovorin in adjuvant colon cancer: Results of the international randomized mosaic trial (abstract 1015). Proc Am Soc Clin Oncol 22:253, 2003.
42. Kemeny N, Jamagin W, Gonen M, et al: Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metasatases from colorectal cancer. J Clin Oncol 21:3303-3309, 2003.